Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetylcysteine + taurine
- Development stage
- Unknown
- Lead developer
- Croise Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cronef-T is an oral fixed-dose combination tablet containing taurine (500 mg) and acetylcysteine (150 mg), developed by Croise Pharma. It is marketed as a nutritional supplement and supportive therapy for the management of chronic kidney disease (CKD) and diabetic kidney disease (diabetic nephropathy). Taurine and acetylcysteine function synergistically as potent antioxidants and cytoprotective agents. They help reduce oxidative stress, protect renal cells from free radical damage, and prevent the deterioration of microalbuminuria, thereby slowing the progression of kidney disease.
- Brand names
- CRONEF-T
- Other names
- acetylcysteine and taurinetaurine + acetylcysteinetaurine and acetylcysteine
02
Targets
SLC7A11 (Cystine-Glutamate Antiporter)
Beyond the preview
Go deeper on acetylcysteine + taurine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetylcysteine + taurine.